Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Veracyte announced new STAMPEDE Phase III data showing its Decipher Prostate test predicts which very high-risk, nonmetastatic prostate cancer patients benefit from adding abiraterone to androgen deprivation therapy. At five years, absolute benefit in reducing distant metastasis was 10-11% for patients with high/very high Decipher scores versus 2% for lower scores, with a statistically significant treatment-by-Decipher interaction (p=0.01).
Key figures
- Drug Name
- Decipher Prostate Genomic Classifier
- Phase Of Trial
- Phase 3
- Interaction p value
- 0.01
- Real world cohort patients
- 27000
- Stampede analysis patients
- 401
- Absolute benefit high scores 5yr
- 10%
- Absolute benefit lower scores 5yr
- 2%
- Absolute benefit very high scores 5yr
- 11%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.